Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 13/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554493 | 1.00 | KDR (0.60) | KDRTEKEGFRERBB2RIPK2 | |
| SCHEMBL5552571 | 0.89 | EGFR (0.70) | EGFRERBB2ERBB4TTBK1TTBK2 | |
| SCHEMBL5552576 | 0.89 | EGFR (0.70) | EGFRERBB2ERBB4TTBK1TTBK2 | |
| SCHEMBL5548965 | 0.86 | EGFR (0.52) | EGFRERBB2ERBB4CLK4CHEK2 | |
| SCHEMBL5548967 | 0.86 | EGFR (0.52) | EGFRERBB2ERBB4CLK4CHEK2 | |
| SCHEMBL7242229 | 0.85 | EGFR (0.65) | KDRTEKEGFRERBB2RIPK2 | |
| SCHEMBL27481777 | 0.82 | EGFR (0.63) | KDRTEKEGFRERBB2RIPK2 | |
| SCHEMBL5554548 | 0.81 | EGFR (0.43) | KDREGFRFLT3MEN1BRAF | |
| SCHEMBL5554550 | 0.81 | EGFR (0.43) | KDREGFRFLT3MEN1BRAF | |
| SCHEMBL30819688 | 0.78 | EGFR (0.59) | EGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | KDR 2037/4885TEK 2324/4885EGFR 265/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | KDR 2037/4885TEK 2324/4885EGFR 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.